Brown Rebecca F, Lopez Kerri, Smith Charlotte B, Charles Anthony
Division of Colorectal Surgery, Department of Surgery, University of Maryland, Baltimore.
Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
JAMA. 2025 Jul 24. doi: 10.1001/jama.2025.10234.
Diverticulosis is defined by the presence of multiple outpouchings (diverticula) originating from the intestinal lumen. Diverticulitis is defined as inflammation of these diverticula. The annual incidence of diverticulitis in the US is approximately 180 per 100 000 people, resulting in approximately 200 000 hospital admissions annually and an estimated health care expenditure of more than $6.3 billion/year.
Risk factors for diverticular disease include age older than 65 years, genetic factors such as variant in the tumor necrosis factor superfamily member 15 (TNFSFI5) gene; connective tissue diseases such as polycystic kidney disease, Marfan syndrome, or Ehlers-Danlos syndrome; body mass index 30 or greater; use of opioids, steroids, and nonsteroidal anti-inflammatory medications; hypertension; and type 2 diabetes. Approximately 1% to 4% of patients with diverticulosis will develop acute diverticulitis in their lifetime, which typically presents as left lower quadrant pain associated with nausea, vomiting, fever, and leukocytosis. A contrast-enhanced abdominal and pelvic computed tomography scan is the recommended diagnostic test and has a sensitivity of 98% to 99% and specificity of 99% to 100%. Approximately 85% of people with acute diverticulitis have uncomplicated diverticulitis (absence of abscess, colon strictures, colon perforation, or fistula formation). Management of patients with uncomplicated diverticulitis consists of observation with pain management (typically acetaminophen) and dietary modification with a clear liquid diet. Antibiotics should be reserved for patients with systemic symptoms such as persistent fever or chills, those with increasing leukocytosis, those older than 80 years, those who are pregnant, those who are immunocompromised (receiving chemotherapy, or high-dose steroids, or have received an organ transplant), and those with chronic medical conditions (such as cirrhosis, chronic kidney disease, heart failure, or poorly controlled diabetes). First-line antibiotics consist of oral amoxicillin/clavulanic acid or cefalexin with metronidazole. For patients who cannot tolerate oral intake, intravenous antibiotic therapy (ie, cefuroxime or ceftriaxone plus metronidazole or ampicillin/sulbactam) is appropriate. Complicated diverticulitis is managed with intravenous antibiotics such as ceftriaxone plus metronidazole or piperacillin-tazobactam and additional invasive management as indicated (ie, percutaneous drainage of associated intra-abdominal abscess or colon resection). Patients with generalized peritonitis should undergo emergent laparotomy with colonic resection. Postoperative mortality for diverticulitis managed electively or emergently is 0.5% for elective colon resection and 10.6% for emergent colon resection.
In the US, diverticulitis affects approximately 180 per 100 000 people annually. For uncomplicated diverticulitis, first-line therapy is observation and pain control, and antibiotics should be initiated for patients with persistent fevers, increasing leukocytosis, sepsis or septic shock, advanced age, pregnancy, immunocompromise, and certain chronic medical conditions. Treatment of complicated diverticulitis includes intravenous antibiotics, such as ceftriaxone plus metronidazole or piperacillin-tazobactam, and, if indicated, percutaneous drainage of abscess or resection of diseased segment of colon.
憩室病是由源自肠腔的多个外突(憩室)的存在所定义的。憩室炎被定义为这些憩室的炎症。在美国,憩室炎的年发病率约为每10万人中有180例,每年导致约20万例住院治疗,估计每年的医疗保健支出超过63亿美元。
憩室病的危险因素包括年龄大于65岁、遗传因素,如肿瘤坏死因子超家族成员15(TNFSFI5)基因变异;结缔组织疾病,如多囊肾病、马凡综合征或埃勒斯-当洛综合征;体重指数为30或更高;使用阿片类药物、类固醇和非甾体抗炎药;高血压;以及2型糖尿病。憩室病患者中约1%至4%在其一生中会发生急性憩室炎,通常表现为左下腹疼痛,并伴有恶心、呕吐、发热和白细胞增多。推荐的诊断检查是增强腹部和盆腔计算机断层扫描,其敏感性为98%至99%,特异性为99%至100%。约85%的急性憩室炎患者患有非复杂性憩室炎(无脓肿、结肠狭窄、结肠穿孔或瘘管形成)。非复杂性憩室炎患者的管理包括观察并进行疼痛管理(通常使用对乙酰氨基酚)以及通过清流食进行饮食调整。抗生素应仅用于有全身症状的患者,如持续发热或寒战、白细胞增多、年龄大于80岁、孕妇、免疫功能低下(接受化疗、或大剂量类固醇、或接受过器官移植)以及患有慢性疾病(如肝硬化、慢性肾病、心力衰竭或控制不佳的糖尿病)的患者。一线抗生素包括口服阿莫西林/克拉维酸或头孢氨苄加甲硝唑。对于无法耐受口服摄入的患者,静脉抗生素治疗(即头孢呋辛或头孢曲松加甲硝唑或氨苄西林/舒巴坦)是合适的。复杂性憩室炎的治疗使用静脉抗生素,如头孢曲松加甲硝唑或哌拉西林-他唑巴坦,并根据需要进行额外的侵入性管理(即经皮引流相关的腹腔内脓肿或结肠切除术)。患有弥漫性腹膜炎的患者应接受紧急剖腹手术并进行结肠切除术。择期或急诊治疗憩室炎的术后死亡率,择期结肠切除术为0.5%,急诊结肠切除术为10.6%。
在美国,憩室炎每年影响约每10万人中有180人。对于非复杂性憩室炎,一线治疗是观察和疼痛控制,对于持续发热、白细胞增多、败血症或感染性休克、高龄、妊娠、免疫功能低下以及某些慢性疾病的患者应开始使用抗生素。复杂性憩室炎的治疗包括静脉抗生素,如头孢曲松加甲硝唑或哌拉西林-他唑巴坦,并在必要时经皮引流脓肿或切除患病结肠段。